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Abstract 
Many studies have suggested that CXCR3, CXCR5, CXCR6 and CXCR7 chemokine receptors play a 
crtical role in the autoimmune process and in β-cell destruction in type 1 diabetes (T1D). In particular 
circulating CXCL10 level (the ligand of CXCR3) is high in T1D patients, and this suggests that 
CXCL10 may be a candidate for a predictive marker of T1D. Blocking the CXCL10/CXCR3 axis in 
newly onset of diabetes seems to be a possible approach for the therapy of T1D. Attempts have been 
done in modulating or blocking CXCR5, CXCR6 and CXCR7 chemokine receptors in experimental 
settings of T1D. Further studies are needed to investigate interactions between chemokines and 
cytokines in the pathogenesis and therapy of T1D. 
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Introduction   
 
Diabetes mellitus type 1 (also known as type 1 diabetes, or T1DM; or insulin-dependent diabetes or 
juvenile diabetes) is a form of diabetes mellitus that results from the autoimmune destruction of the 
insulin-producing β-cells in the pancreas. The subsequent lack of insulin leads to increased blood 
glucose. T1D is an immunologically mediated disease, in which a T helper (Th)1 immune response 
leading β-cells destruction has been shown [1], involving an expansion of autoreactive CD4+ Th cells 
and CD8+ T cells, autoantibody-producing B cells and activation of the innate immune system [2-4]. 
As the key immunological mechanisms of the pathogenesis of this disease are still unclear [5, 6], 
prevention and treatment of T1D are hampered.  
Cytokines and chemokines, and their receptors, play an important role in the pathogenesis of T1D and 
are targets of new therapeutic approaches. Here, we review researches about (C-X-C motif) receptor 
(CXCR)3, CXCR5, CXCR6 and CXCR7 chemokine receptors in T1D. 
 
CXCR3 and diabetes 
CXCR3 and its chemokines 
CXCR3 receptor is mostly expressed on activated Th1 cells. It is a seven-transmembrane G-protein 
coupled chemokine receptor, that is determinant in a variety of inflammatory and immunological 
disorders. (C-X-C motif) ligand (CXCL)10/interferon (IFN)-γ-induced protein 10 (IP-10), 
CXCL9/monokine induced by IFN-γ (MIG) and CXCL11/Interferon Inducible T cell α (ITAC) are its 
ligands. They are expressed by infiltrating leukocytes, endothelial cells, fibroblasts and by epithelial 
cells following stimulation by IFN-γ or Type I IFNs; their expression is synergistically enhanced by 
tumor necrosis factor (TNF)-α [7-11]. 
In transplant rejection, a critical role for CXCR3-dependent T cell recruitment is suggested by the 
strong upregulation of CXCR3 ligand expression and the prevalent expression of CXCR3 on 
infiltrating T cells during allograft rejection in human and animal models [12-14]. The potential 
importance of CXCR3-mediated leukocyte recruitment in the pathology of autoimmune disorders is 
indicated by the upregulation of CXCR3 ligands and the increased number of CXCR3+ lymphocytes 
evidenced in chronic inflammatory diseases, as rheumatoid arthritis (RA) [15-18], systemic lupus 
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erythematosus (SLE) (19), inflammatory arthritis (19), and multiple sclerosis [20, 21]. 
CXCL10/IP-10 is the main CXCR3 ligand and its secretion depends on IFN-γ, that is itself mediated by 
the interleukin (IL)-12 cytokine family [22]. Upon cytokines stimulation, CXCL10 is secreted by 
several cell types, including T lymphocytes, monocytes, fibroblasts, thyrocytes, preadipocytes, etc. 
Therefore, the presence of high levels of CXCL10 in peripheral liquids is a marker of host immune 
response, particularly Th1 orientated T cells.  
Circulating levels of CXCL10 are increasing with age [23]. Furthermore, recent reports have shown 
that the serum and/or the tissue expressions of CXCL10 are increased in organ specific autoimmune 
diseases, such as Graves’ disease or Graves’ ophthalmopathy [24, 25], autoimmune thyroiditis [26, 27], 
or systemic rheumatological disorders like rheumatoid arthritis [28], systemic lupus erythematosus [29], 
systemic sclerosis [30, 31], psoriasis or psoriatic arthritis [32, 33], sarcoidosis [34, 35], HCV-related 
cryoglobulinemia [36, 37], other HCV immune mediated disorders [36-38] and also in liver and thyroid 
cancers [39, 40].  
 
CXCR3 chemokines and diabetes 
The evaluation of circulating levels of CXCL10 in T1D produced different results. Most of the studies 
observed high levels of serum CXCL10 in children and adults with T1D, expecially in newly 
diagnosed T1D [41-44]. Only two studies did not find a CXCL10 increase in T1D serum levels [45, 
46].  
The prototype Th1 chemokine (CXCL10) and the prototype Th2 chemokine (C-C motif) ligand 2 
(CCL2)/monocyte chemotactic protein-1 (MCP-1) have been evaluated longitudinally in children with 
T1D at onset and follow-up [47]. Serum CXCL10 levels were significantly higher in T1D children than 
in relatives or control children, while CCL2 were similar in patients, relatives and control subjects. 
During the follow-up of T1D patients, CXCL10 was significantly reduced, while CCL2 did not change, 
with respect to baseline. This study first shows that in children with newly diagnosed T1D, raised 
serum CXCL10 and normal CCL2 concentrations indicate a predominant Th1-driven autoimmune 
process, which shifts toward Th2 immunity over the first 1-2 years from diagnosis [47]. Studies 
examining the sources of CXCL10 in T1D showed that it was produced by peripheral blood monocytes 
and leukocytes [48, 49]. 
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CXCL10 is highly expressed in lymphocytes infiltrating the human islet; and β-cells, stimulated by 
cytokines (as IFN-γ and TNF-α), can modulate the autoimmune response releasing CXCL9, CXCL10 
and CXCL11. These chemokines induce the migration of Th1 lymphocytes into the islet, that secrete 
more IFN-γ and TNF-α, stimulating a further chemokine production by the target cells, that perpetuates 
the autoimmune cascade. In agreement, CXCL10 has been identified as the prevalent chemokine 
expressed in vivo in the islet environment of prediabetic animals and T1D patients [50-52]. 
For the above mentioned reasons, the CXCL10/CXCR3 chemokine system plays a critical role in the 
autoimmune process and in β-cell destruction in T1D.  
 
Effect of blocking CXCL10 in T1D 
The effect of CXCL10 neutralization using a T1D model initiated by developmentally regulated 
presentation of β-cell antigens has been evaluated. The occurrence of diabetes was suppressed by 
CXCL10 neutralization, after the administration with cyclophosphamide in non-obese diabetic (NOD) 
mice, even if CXCL10 neutralization did not significantly inhibit insulitis and did not influence 
trafficking of effector T cells into the islets. As CXCL10 and CXCR3 were coexpressed on insulin-
producing cells, CXCL10 was considered to affect mature and premature β-cells in an autocrine and/or 
paracrine manner. In fact, CXCL10 neutralization increased the proliferation of β-cells and β-cell mass, 
without inhibiting insulitis. For these reasons, it was suggested that CXCL10 neutralization could be 
considered a new therapeutic target for β-cell survival, during the early stage of T1D and also after islet 
transplantation [53]. 
Another paper evaluated the effect of CXCL10 neutralization in a "spontaneous diabetes" model of 
NOD mice, through CXCL10 DNA vaccination (pCAGGS-CXCL10), that induced the production of 
anti-CXCL10 antibodies (Ab) in vivo and suppressed the incidence of spontaneous diabetes, in young 
NOD mice, without inhibiting insulitis or altering the immunological response. pCAGGS-CXCL10 
treatment increased the proliferation of pancreatic β-cells, causing an increase of β-cell mass in this 
spontaneous diabetes model as well. For these reasons, it has been suggested that CXCL10 
neutralization could be useful for maintaining β-cell mass at any stage of autoimmune diabetes [54]. 
 
CXCR5 and diabetes 
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CXCR5, also known as Burkitt lymphoma receptor 1 (BLR1), belongs to the CXC chemokine receptor 
family, and it is a G protein-coupled seven transmembrane receptor for chemokine CXCL13, encoded 
by the CXCR5 gene [55]. 
The CXCR5 gene is specifically expressed in lymphatic tissues, such as follicles in lymph nodes as 
well as in spleen; it plays an essential role in B cell migration [56, 57]. CXCL13, also known as B 
lymphocyte chemoattractant (BLC), is selectively chemotactic for B cells belonging to both the B-1 
and B-2 subsets. CXCL13 and its receptor CXCR5 control the organization of B cells within follicles 
of lymphoid tissues [58] and is expressed highly in liver, spleen, lymph nodes. In T lymphocytes, 
CXCL13 expression is thought to reflect a germinal center origin of the T cell, particularly a subset of 
T cells called Follicular B Helper T cells (or Tfh cells) [58].  
Lymphocytes that invade nonlymphoid tissues often organize into follicle-like structures known as 
tertiary lymphoid organs (TLOs). These structures resemble those found in spleen or lymph nodes, but 
their function is unknown. TLOs are recognized in the NOD mouse model of T1D. In some cases, 
TLOs have been associated with the B lymphocyte chemoattractant, in fact CXCL13 is present in 
inflamed islets of NOD mice [59]. 
Ab blockade of this chemokine unraveled B lymphocyte organization in islet TLOs, without reducing 
their proportion in the islets. However, loss of B lymphocyte organization in islets did not provide 
disease protection against T1D [60]. Tfh cells exert an important role in autoimmune diseases; to 
investigate the role of Tfh cells in patients with T1D and the effect of anti-CD20 monoclonal antibody 
(rituximab) on Tfh cells in T1D patients, 54 patients with T1D and 37 healthy controls were enrolled, 
and 20 T1D were treated with rituximab. Increased frequencies of circulating Tfh cells together with 
enhanced expression of IL-21 were detected in T1D patients. After rituximab therapy, the frequencies 
of circulating Tfh cells and serum protein-tyrosine-phosphatase-2 autoantibody (IA2A) were decreased, 
together with the levels of IL-21, IL-6 and Bcl-6. Furthermore, β-cell function in 10 of 20 patients was 
improved. These data suggest that Tfh cells may participate in the T1D-related immune responses, and 
in the disease progression [61]. 
 
 
CXCR6 and diabetes 
CXCL16 is a small CXC chemokine, composed of a CXC chemokine domain, a transmembrane 
domain and a cytoplasmic tail containing a potential tyrosine phosphorylation [62]. CXCL16 is 
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produced by dendritic cells found in the T cell zones of lymphoid organs, and by cells found in the 
spleen [62]. Cells that bind and migrate in response to CXCL16 include several subsets of T cells, and 
natural killer T cells [62]. CXCL16 interacts with the chemokine receptor CXCR6, also known as 
Bonzo [62, 63]. Expression of CXCL16 is induced by the inflammatory cytokines IFN-γ and TNF-α 
[63, 64]. 
Mesenchymal stem cells (BM-MSCs) are stromal cells with the ability to proliferate and differentiate 
into many tissues. A minority of BM-MSCs (2% to 25%) expressed a restricted set of chemokine 
receptors [CXCR4, chemokine (C-X3-C motif) receptor 1 (CX3CR1), CXCR6, (C-C motif) receptor 
(CCR) 1, CCR7] and, accordingly, showed appreciable chemotactic migration in response to the 
chemokines CXCL12, chemokine (C-X3-C motif) ligand 1 (CX3CL1), CXCL16, CCL3, and CCL19. 
A population of bona fide MSCs that also expressed CXCR4, CXCR6, CCR1, and CCR7 could be 
isolated from normal adult human pancreas [65]. Enteroviruses, particularly Coxsackie virus B4 
(CVB4), are considered to be involved in the pathogenesis of T1D [66]. A study compared the 
characteristics of T cell immune response to CVB4 in children with T1D and healthy children with and 
without human leukocyte antigen (HLA) risk-associated haplotypes (HLA-DR3-DQ2 or HLA-DR4-
DQ8) for T1D. Peripheral blood mononuclear cells (PBMCs) showed, in children with T1D, a 
decreased percentage of T cells expressed CCR2, CXCR6, IL-18R, and IL-12Rβ2-chain after in vitro 
stimulation with CVB4 in comparison with healthy children. Moreover, children with T1D had 
decreased IFN-γ secretion in CVB4-stimulated PBMCs, suggesting an impaired type 1 immune 
response against CVB4. This may lead to a delayed clearance of the virus and, at least partly, explain 
why children with T1D may be more prone to CVB4 infections and related complications, such as β-
cell damage [67]. 
Since chemokines and chemokine receptors are key players in the migration of pathogenic T cells into 
the islets of NOD mice developing T1D, it was studied the expression of Th1- and Th2-associated 
chemokine receptors, and the two isoforms of CD45 leucocyte antigen on CD4(+) and CD8(+) 
lymphocytes from T1D and healthy children. It has been shown an increased expression of CCR7 and 
CD45RA and reduced CD45RO on CD8(+) cells among recent-onset T1D patients. The percentages of 
CD4(+) cells expressing CXCR3, CXCR6 and CCR5, and the secretion of CXCL10/IP-10, MCP-1, 
macrophage inflammatory protein (MIP)-1α and MIP-1β was lower among diabetics. The Authors 
suggest that low expression of Th1-associated receptors and secretion of chemokines, together with an 
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increased amount of CD8(+) cells expressing CD45RA and CCR7 in T1D patients therefore might 
represent suboptimal Th function in T1D, leading to impaired T cytotoxic responses [68]. 
A prior exposure to Complete Freund's Adjuvant (CFA) suppresses the severity of experimental 
autoimmune encephalomyelitis (EAE) and spontaneous diabetes in rodents. It has been shown that 
CFA adjuvant immunotherapy of EAE requires IFN-γ, which suppresses development of the Th17 
response, and diverts autoreactive T cells away from the central nervous system toward immature 
myeloid cells expressing CXCL10 and CXCL16 in the lymph nodes, suggesting a similar mechanism 
in T1D [69].  
 
CXCR7 and diabetes 
CXCR7 belongs to G protein-coupled receptor family, and it is a chemokine receptor able to bind the 
chemokines CXCL12/stromal cell-derived factor-1 (SDF-1) and CXCL11 [70, 71]. 
Genome-wide association studies (GWAS) have heralded a new era in susceptibility locus discovery in 
complex diseases. For T1D, >40 susceptibility loci have been discovered. A study integrated T1D 
GWAS data with protein-protein interactions to construct biological networks of relevance for disease. 
A total of 17 networks were identified. To substantiate these networks, it was performed expressional 
profiling in human pancreatic islets exposed to proinflammatory cytokines. Three networks were 
significantly enriched for cytokine-regulated genes and, thus, likely to play an important role for T1D 
in pancreatic islets. Eight of the regulated genes (CD83, IFNGR1, IL-17RD, TRAF3IP2, IL-27RA, 
PLCG2, MYO1B, and CXCR7) in these networks also harbored single nucleotide polymorphisms 
nominally associated with T1D. Finally, the expression and cytokine regulation of these new candidate 
genes were confirmed in insulin-secreting INS-1 β-cells. These results provide novel insight to the 
mechanisms behind T1D pathogenesis and, thus, may provide the basis for the design of novel 
treatment strategies [72]. 
 
Conclusion 
The above mentioned studies have suggested that CXCR3, CXCR5, CXCR6 and CXCR7 chemokine 
receptors play a crtical role in the autoimmune process and in β-cell destruction in TID. In particular 
serum CXCL10 is high in T1D patients, and this suggests that CXCL10 may be a candidate for a 
predictive marker of T1D. Blocking the CXCL10/CXCR3 axis in newly onset of diabetes seems to be a 
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possible approach for the therapy of T1D. Attempts have been done in modulating or blocking CXCR5, 
CXCR6 and CXCR7 chemokine receptors in experimental settings of T1D. 
Further studies are needed to investigate interactions between chemokines and cytokines in the 
pathogenesis and therapy of T1D. 
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